Table 4.
ProBNP1-108 | BNP32 | |||||
---|---|---|---|---|---|---|
HR, Tertile 2 versus 1 (95% CI)§ | HR, Tertile 3 versus 1 (95% CI)§ | HR per 2-fold increase in proBNP1-108 (95% CI) | HR, Tertile 2 versus 1 (95% CI)§ | HR, Tertile 3 versus 195% CI§ | HR per 2-fold increase in BNP1-32 (95% CI) | |
Unadjusted | 3.1 (2.3–4.3) | 4.4 (2.3–4.3) | 1.3 (1.2–1.3) | 2.2 (1.6–3.0) | 3.8 (2.9–5.1) | 1.3 (1.2–1.3) |
Model 1* | 3.1 (2.2–4.2) | 4.3 (3.1–6.0) | 1.3 (1.2–1.3) | 2.2 (1.6–3.0) | 3.7 (2.7–5.0) | 1.2 (1.2–1.3) |
Model 2† | 2.7 (1.9–3.8) | 3.4 (2.3–4.8) | 1.2 (1.2–1.3) | 1.9 (1.4–2.7) | 2.8 (2.0–3.9) | 1.2 (1.1–1.3) |
Model 3‡ | 2.4 (1.7–3.3) | 2.5 (1.7–3.6) | 1.2 (1.1–1.2) | 1.8 (1.3–2.5) | 2.1 (1.5–3.0) | 1.1 (1.1–1.2) |
Model 1 adjusted for age, sex, race, tobacco, creatinine, body mass index
Model 2 adjusted for Model 1 + EF + cardiomyopathy etiology (ischemic versus non-ischemic)
Model 3 adjusted for Model 2 + NYHA Class (I/II versus III/IV)
all p<0.001, including test for trend